On September 7, 2021 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences (Press release, Kura Oncology, SEP 7, 2021, View Source [SID1234587315]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand beginning at 7:00 a.m. ET / 4:00 a.m. PT on September 13, 2021; and

A pre-recorded fireside chat at the Cantor Global Healthcare Conference, available at 3:20 p.m. ET / 12:20 p.m. PT on September 27, 2021.
Audio webcasts of the H.C. Wainwright and Cantor events will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.

On September 7, 2021 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, reported that Clive Richardson, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021 (Press release, Akari Therapeutics, SEP 7, 2021, https://www.akaritx.com/2021/09/07/akari-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference/ [SID1234587314]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the H.C. Wainwright conference coordinator. A webcast of the Company’s presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. ET by visiting ‘Events’ in the Investor Relations section on the Company’s website at www.akaritx.com. A webcast replay will be accessible for 90 days following the event.

On September 7, 2021 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported that management will participate in three upcoming investor conferences (Press release, IGM Biosciences, SEP 7, 2021, View Source [SID1234587313]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 16th Annual BioPharma Virtual Conference on Thursday, September 9
Fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13 at 2:45 p.m. EDT
Fireside chat at Baird’s 2021 Global Consumer, Technology & Services Conference on Tuesday, September 14 at 2:35 p.m. EDT
A live webcast of the Morgan Stanley fireside chat will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

On September 7, 2021 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that Richard Paulson, President and Chief Executive Officer, will participate in the following virtual investor conferences in September (Press release, Karyopharm, SEP 7, 2021, View Source [SID1234587312]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investment Conference
Format: Podium presentation
Date: Monday, September 13, 2021
Time: 7:00 AM Eastern Time

Morgan Stanley 19th Annual Global Healthcare Conference
Format: Fireside chat
Date: Monday, September 13, 2021
Time: 11:00 AM Eastern Time

Baird 2021 Global Healthcare Conference
Format: Fireside chat
Date: Tuesday, September 14, 2021
Time: 2:00 PM Eastern Time

A live webcast of the fireside chats and a replay of the H.C. Wainwright presentation can be accessed under "Events & Presentations" in the Investor section of the Company’s website, View Source A replay of the webcasts will be archived on the Company’s website for 30 days following the presentation and fireside chats.

On September 7, 2021 Bristol Myers Squibb (NYSE: BMY) reported that the company will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Virtual Conference, which will be webcast on Tuesday, September 14, 2021 (Press release, Bristol-Myers Squibb, SEP 7, 2021, View Source [SID1234587311]). Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, will answer questions about the company at 8 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source An archived edition of the session will be available later that day.